(Q35194383)

7 August 2017

title

Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease (English)

1 reference

7 August 2017

1 reference

1 reference

Reina Benabou

1

1 reference

7 August 2017

Cheryl Waters

series ordinal

2

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

Expert Opinion on Drug Safety

7 August 2017

published in

1 reference

7 August 2017

volume

2

1 reference

7 August 2017

issue

3

1 reference

7 August 2017

page(s)

263-267

1 reference

Recent advances in the genetics and pathogenesis of Parkinson disease

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

Comparative tolerability of the newer generation antiparkinsonian agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

Treatment of advanced stage patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

Twelve-month safety of entacapone in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

Clinical pharmacokinetics of anti-parkinsonian drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

Dopamine is a monoamine oxidase B substrate in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

Entacapone in the management of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

The rise and fall of tolcapone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

Tolcapone and hepatotoxic effects. Tasmar Advisory Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

Entacapone-induced hepatotoxicity and hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson's disease, does not impair mitochondrial energy production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

Effects of entacapone and tolcapone on mitochondrial membrane potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

Different toxicological profile of two COMT inhibitors in vivo: the role of uncoupling effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

Transamination is a Major Pathway of L-Dopa Metabolism following Peripheral Decarboxylase Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.2.3.263

21 January 2018

Identifiers

DOI

10.1517/14740338.2.3.263

1 reference

7 August 2017

1 reference